The Food and Drug Administration told makers of experimental COVID-19 vaccines that, in order to request emergency approval, they need to provide at least two months of follow-up data after trial participants received their final injection.
The new requirement – listed within the agency’s newly published guidelines for Emergency Use Authorization (EAU) – creates an unlikely timeline for drugmakers to receive approval by November 3.
As part of its updated requirements, the FDA noted that vaccine makers should follow participants for a minimum of two months after receiving their final dosage in an effort to rule out any major side effects before submitting candidates for EAU approval.
This data will help to “provide adequate information to assess a vaccine’s benefit-risk profile including adverse events; cases of severe COVID-19 disease among study subjects; and cases of COVID-19 occurring during the timeframe when adaptive (rather than innate) and memory immune responses to the vaccine would be responsible for a protective effect,” the guidelines state.
The requirements are aimed at companies seeking rapid approval through the FDA’s emergency authorization pathway. That accelerated process, reserved for health emergencies, allows medical products onto the market based on a lower bar than traditional FDA approval.
But the FDA has made clear only vaccines that are shown to be safe and effective will be authorized for coronavirus.
However, a senior administration official confirmed Monday that the White House had blocked the FDA’s plans to formally publish the safety guidelines regarding the two-month data requirement, arguing there was “no clinical or medical reason” for it.
However, this didn’t stop the agency, which posted the guidance on its website a day later, making clear that regulators plan to impose the safety standards for any vaccine seeking an expedited path to market.